Literature DB >> 31695436

Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5'UTR.

Cobra Moradian1, Fatemeh Rahbarizadeh1.   

Abstract

BACKGROUND: Breast cancer stem cells (BCSCs) are cells with a higher ability to metastasis and resistance to conventional treatments. They have a phenotype of (CD44high/CD24low) and the unlimited ability for proliferation. Development of strategies to target the BCSC population may lead to the establishment of more effective cancer therapies. Pseudomonas exotoxin A (PE) is a potent cytotoxic protein. CXCR1 promoter provides BCSC and HER2 specificity on transcription level. 5'UTR of the basic fibroblast growth factor-2 (bFGF 5'UTR) provides tumor specificity on translation level. Here, we utilized a mutant form of PE encoding DNA "PE38", CXCR1 promoter and bFGF 5'UTR to target BCSCs.
METHODS: The stemness of SK-BR-3, MDA-MB-231 and MCF10A cell lines were evaluated based on the expression of the CD44high/CD24low stem cell signature and the ability to form mammospheres. Then, the cell lines were transfected with constructs encoding luciferase/PE38 under the control of the CMV/CXCR1 promoter with or without bFGF 5'UTR. Luciferase protein expression was evaluated using dual-luciferase reporter assay. PE38 transcript expression was measured by real-time PCR, and the cytotoxic effect of PE38 protein expression was determined by MTT assay.
RESULTS: The percentage of CD44high/CD24low population did not correlate to mammosphere forming efficiency (MFE). Given that the percentage of CD44 high/CD24 low is not a conclusive BCSC profile, we based our work on the mammosphere assay. However, in comparison with MCF10A, the two tumorigenic cell lines had higher MFE, probably due to their higher BCSC content. Reporter assay and real-time PCR results demonstrated that CXCR1 promoter combined with bFGF 5'UTR increased BCSC-specific gene expression. Meanwhile, tightly regulated expression of PE38 using these two gene regulatory elements resulted in high levels of cell death in the two tumorigenic cell lines while having little toxicity toward normal MCF10A.
CONCLUSION: Our data show that PE38, CXCR1 promoter and bFGF 5'UTR in combination can be considered as a promising tool for killer gene therapy of breast cancer.
© 2019 Moradian and Rahbarizadeh.

Entities:  

Keywords:  CXCR1 promoter; HER2; PE38; bFGF-2; breast cancer stem cell; mammosphere

Year:  2019        PMID: 31695436      PMCID: PMC6821057          DOI: 10.2147/OTT.S221223

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


  36 in total

1.  PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy.

Authors:  Fereydoon Abedi-Gaballu; Gholamreza Dehghan; Maryam Ghaffari; Reza Yekta; Soheil Abbaspour-Ravasjani; Behzad Baradaran; Jafar Ezzati Nazhad Dolatabadi; Michael R Hamblin
Journal:  Appl Mater Today       Date:  2018-05-29

2.  Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Authors:  Marianela Candolfi; Weidong Xiong; Kader Yagiz; Chunyan Liu; A K M G Muhammad; Mariana Puntel; David Foulad; Ali Zadmehr; Gabrielle E Ahlzadeh; Kurt M Kroeger; Matthew Tesarfreund; Sharon Lee; Waldemar Debinski; Dhruv Sareen; Clive N Svendsen; Ron Rodriguez; Pedro R Lowenstein; Maria G Castro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

3.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.

Authors:  Tiffany M Phillips; William H McBride; Frank Pajonk
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

4.  Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.

Authors:  J Michael Mathis; B Jill Williams; Don A Sibley; Jennifer L Carroll; Jie Li; Yoshinobu Odaka; Shayne Barlow; Cherie-Ann O Nathan; Benjamin D L Li; Arrigo DeBenedetti
Journal:  J Gene Med       Date:  2006-09       Impact factor: 4.565

5.  Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells.

Authors:  I B Rosenwald
Journal:  Cancer Lett       Date:  1996-04-19       Impact factor: 8.679

6.  A cancer gene therapy approach through translational control of a suicide gene.

Authors:  Robert J DeFatta; Robert P Chervenak; Arrigo De Benedetti
Journal:  Cancer Gene Ther       Date:  2002-06       Impact factor: 5.987

7.  Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes.

Authors:  N D Sonawane; Francis C Szoka; A S Verkman
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

8.  let-7 regulates self renewal and tumorigenicity of breast cancer cells.

Authors:  Fengyan Yu; Herui Yao; Pengcheng Zhu; Xiaoqin Zhang; Qiuhui Pan; Chang Gong; Yijun Huang; Xiaoqu Hu; Fengxi Su; Judy Lieberman; Erwei Song
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

9.  Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting.

Authors:  Yu Xiang Fang; Xiao Bo Zhang; Wei Wei; Yi Wen Liu; Jin Zhong Chen; Jing Lun Xue; Ling Tian
Journal:  Mol Biotechnol       Date:  2010-05       Impact factor: 2.695

10.  Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.

Authors:  Matthew J Grimshaw; Lucienne Cooper; Konstantinos Papazisis; Julia A Coleman; Hermann R Bohnenkamp; Laura Chiapero-Stanke; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  Breast Cancer Res       Date:  2008-06-09       Impact factor: 6.466

View more
  2 in total

Review 1.  Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.

Authors:  Seyed Mehdi Havaei; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 2.  From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?

Authors:  Matteo Ardini; Riccardo Vago; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Toxins (Basel)       Date:  2022-08-23       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.